Evidence map›Paper›PMID 33606988›Full record

ArticleStem cell reports2021

Unraveling the Developmental Roadmap toward Human Brown Adipose Tissue.

Stefania Carobbio, Anne-Claire Guenantin, Myriam Bahri, Sonia Rodriguez-Fdez, Floris Honig, Ioannis Kamzolas, Isabella Samuelson, Kathleen Long, Sherine Awad, Dunja Lukovic and 7 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Stem cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. PGEThe EMBO journal · 2022
    Article
  12. Review
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Stefania CarobbioWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK; Metabolic Research Laboratories, Addenbrooke's Treatment Centre, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK. Electronic address: sc22@sanger.ac.uk.
Anne-Claire GuenantinWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK; Metabolic Research Laboratories, Addenbrooke's Treatment Centre, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Myriam BahriWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Sonia Rodriguez-FdezWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Floris HonigWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Ioannis KamzolasMetabolic Research Laboratories, Addenbrooke's Treatment Centre, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK.
Isabella SamuelsonWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK; Metabolic Research Laboratories, Addenbrooke's Treatment Centre, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Kathleen LongWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Sherine AwadMetabolic Research Laboratories, Addenbrooke's Treatment Centre, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Dunja LukovicRetinal Degeneration Lab and National Stem Cell Bank-Valencia Node, Research Center Principe Felipe, Valencia, Spain.
Slaven ErcegStem Cell Therapies for Neurodegenerative Diseases Lab and National Stem Cell Bank - Valencia Node, Research Center Principe Felipe, Valencia, Spain.
Andrew BassettWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Sasha MendjanInstitute of Molecular Biotechnology, 1030 Vienna, Austria.
Ludovic VallierWellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK; Department of Surgery, University of Cambridge, Cambridge, UK.
Barry S RosenWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Davide ChiarugiMetabolic Research Laboratories, Addenbrooke's Treatment Centre, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Antonio Vidal-PuigWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK; Metabolic Research Laboratories, Addenbrooke's Treatment Centre, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK; Cambridge University Nanjing Centre of Technology and Innovation, Jiangbei Area, Nanjing, P.R. China. Electronic address: ajv22@medschl.cam.ac.uk.
Wellcome Sanger Institute · GBAddenbrooke's Hospital · GBCentro de Investigacion Principe Felipe · ESUniversity of Cambridge · GBInstitute of Molecular Biotechnology · ATWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

British Heart Foundation RG/18/7/33636Medical Research Council G0701448Medical Research Council MC_PC_17230Medical Research Council MC_UU_00014/2National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/N001540/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/T2T0419Wellcome Trust
6 · The paper itself

Abstract

Increasing brown adipose tissue (BAT) mass and activation is a therapeutic strategy to treat obesity and complications. Obese and diabetic patients possess low amounts of BAT, so an efficient way to expand their mass is necessary. There is limited knowledge about how human BAT develops, differentiates, and is optimally activated. Accessing human BAT is challenging, given its low volume and anatomical dispersion. These constraints make detailed BAT-related developmental and functional mechanistic studies in humans virtually impossible. We have developed and characterized functionally and molecularly a new chemically defined protocol for the differentiation of human pluripotent stem cells (hPSCs) into brown adipocytes (BAs) that overcomes current limitations. This protocol recapitulates step by step the physiological developmental path of human BAT. The BAs obtained express BA and thermogenic markers, are insulin sensitive, and responsive to β-adrenergic stimuli. This new protocol is scalable, enabling the study of human BAs at early stages of development.

Indexed as

AdipogenesisThermogenesisAdipocytes, BrownAdipose Tissue, BrownBiomarkersCell Culture TechniquesCell DifferentiationCell LineGene Expression Regulation, DevelopmentalHumansPluripotent Stem CellsReproducibility of ResultsTranscription FactorsBiomarkersTranscription FactorsBAT progenitorsbrown adipose tissuedevelopmentdifferentiationhuman pluripotent stem cellsthermogenesis

Identifiers

PMID33606988
PMCPMC7940445
OpenAlexW3131190171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.